PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
Objective: to study the possibility of prediction of treatment effectiveness with tocilizumab and rituximab in rheumatoid arthritis (RA), taking into account the clinical and immunological characteristics of patients. Material and methods. The efficacy of treatment with tocilizumab in 53 patients and rituximab in 22 patients with RA within 12 months was analyzed, the prognostic role of the initial values of activity indices, the presence of systemic manifestations, the duration of RA, levels of autoantibodies and acute phase proteins was evaluated. Results. The high efficacy of treatment with biological drugs in RA was established, the treatment goals were achieved by 84.91% of patients in the group of tocilizumab and 72.72% in the group of rituximab, but the remaining patients did not reach the treatment goal after 12 months of follow-up. Conclusions. Reliable predictors of a good response to tocilizumab in RA may be high activity of the joint syndrome, rituximab – seropositive variant of RA, as well as the presence of systemic manifestations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta - 17(2019), 5, Seite 560-564 |
| Sprache: |
bel ; Englisch ; Russisch |
|---|
| Beteiligte Personen: |
Volkava M. V. [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Medicine |
|---|
| doi: |
10.25298/2221-8785-2019-17-5-560-564 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ031928536 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ031928536 | ||
| 003 | DE-627 | ||
| 005 | 20230503013004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2019 xx |||||o 00| ||bel c | ||
| 024 | 7 | |a 10.25298/2221-8785-2019-17-5-560-564 |2 doi | |
| 035 | |a (DE-627)DOAJ031928536 | ||
| 035 | |a (DE-599)DOAJ103eef832afc4328a8b8739f7bd44c71 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a bel |a eng |a rus | ||
| 100 | 0 | |a Volkava M. V. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: to study the possibility of prediction of treatment effectiveness with tocilizumab and rituximab in rheumatoid arthritis (RA), taking into account the clinical and immunological characteristics of patients. Material and methods. The efficacy of treatment with tocilizumab in 53 patients and rituximab in 22 patients with RA within 12 months was analyzed, the prognostic role of the initial values of activity indices, the presence of systemic manifestations, the duration of RA, levels of autoantibodies and acute phase proteins was evaluated. Results. The high efficacy of treatment with biological drugs in RA was established, the treatment goals were achieved by 84.91% of patients in the group of tocilizumab and 72.72% in the group of rituximab, but the remaining patients did not reach the treatment goal after 12 months of follow-up. Conclusions. Reliable predictors of a good response to tocilizumab in RA may be high activity of the joint syndrome, rituximab – seropositive variant of RA, as well as the presence of systemic manifestations. | ||
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a tocilizumab | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a treatment efficacy | |
| 650 | 4 | |a predictors | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta |d Grodno State Medical University, 2018 |g 17(2019), 5, Seite 560-564 |w (DE-627)DOAJ000066737 |x 24130109 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2019 |g number:5 |g pages:560-564 |
| 856 | 4 | 0 | |u https://doi.org/10.25298/2221-8785-2019-17-5-560-564 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/103eef832afc4328a8b8739f7bd44c71 |z kostenfrei |
| 856 | 4 | 0 | |u http://journal-grsmu.by/index.php/ojs/article/view/2459 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2221-8785 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2413-0109 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2019 |e 5 |h 560-564 | ||